Competitive PressurePharma's outlook remains cautious with expected flat organic growth and a forecasted significant drop in Xarelto revenues due to competition from generic products.
Financial PerformanceQ1 shows a potential slow start with significant decline in earnings before interest, taxes, depreciation, and amortization due to challenges in Crop Science and increased expenses.
Sector ChallengesConsumer Health likely to experience a decline in EBITDA due to increased marketing investments and material foreign exchange headwind.